SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

OS Therapies Inc

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

68764Y207

(CUSIP Number)

Shalom Auerbach
15 Atlantic Avenue,, Suite M2
Lynbrook, NY, 11563
917-364-7051

Einodmil LLC
396 Oakland Avenue,,
Cedarhurst, NY, 11516
917-364-7051

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/29/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.	68764Y207

1	**Name of reporting person** Shalom Auerbach
2	**Check the appropriate box if a member of a Group (See Instructions)** ☐ (a) ☐ (b)

3	SEC use only	
4	Source of funds (See Instructions) AF, PF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 2,677,570.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 2,677,570.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 2,677,570.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 8.5 %	
14	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person:
See Item 5 for additional information.

SCHEDULE 13D

CUSIP No.	68764Y207

1	Name of reporting person Einodmil LLC
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

6	**Citizenship or place of organization** DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 — **Sole Voting Power** 2,654,199.00 8 — **Shared Voting Power** 0.00 9 — **Sole Dispositive Power** 2,654,199.00 10 — **Shared Dispositive Power** 0.00
11	**Aggregate amount beneficially owned by each reporting person** 2,654,199.00
12	**Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)** ☐
13	**Percent of class represented by amount in Row (11)** 8.4 %
14	**Type of Reporting Person (See Instructions)** OO

Comment for Type of Reporting Person:
See Item 5 for additional information.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value $0.001 per share

(b) Name of Issuer:

OS Therapies Inc

(c) Address of Issuer's Principal Executive Offices:

115 Pullman Crossing Road, Suite #103, Grasonville, MARYLAND , 21638.

Item 1 Comment:
Item 1 of the Schedule 13D is hereby supplemented as follows: This Amendment No. 4 (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons (as defined in Item 2 of the Schedule 13D) with the SEC (as defined in Item 5 of the Schedule 13D) on January 17, 2025 (the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported on the Schedule 13D or the Schedule 13D/A filed by the Reporting Persons with the SEC on February 28, 2025 ("Amendment No. 1"), March 12, 2025 ("Amendment No. 2") and May 9, 2025 ("Amendment No. 3"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D, Amendment No 1, Amendment No. 2 and Amendment No. 3, as applicable. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment and the information set forth in or incorporated by reference in Item 5 of this Amendment is hereby incorporated by reference in its entirety into this Item 3.

On July 3, 2025, Einodmil sold 10,000 shares of Common Stock, which were effected on the open market at a price per share of approximately $2.10 for proceeds of approximately $20,695 (the "July 3, 2025 Sales").

Item 5. Interest in Securities of the Issuer

(a) Item 5 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment is hereby incorporated by reference in its entirety into this Item 5.

As of the date hereof, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 8.5% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of the date hereof, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 8.4% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of July 29, 2025, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 8.5% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

As of July 29, 2025, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 8.4% of the Issuer's outstanding shares of Common Stock (based on 31,624,076 shares of Common Stock issued and outstanding as of July 29, 2025 as reported by the Issuer in its Registration Statement on Form S-1 filed with the SEC on August 4, 2025).

(b) As of the date hereof, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power.

As of July 29, 2025, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,677,570 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,654,199 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power.

(c) Except for the July 3, 2025 Sales, there were no other transactions by the Reporting Persons in shares of Common Stock as of the date hereof or during the period commencing sixty (60) days prior to the date hereof.

Except for the July 3, 2025 Sales, there were no other transactions by the Reporting Persons in shares of Common Stock as of July 29, 2025 or during the period commencing sixty (60) days prior to July 29, 2025.

Item 7. Material to be Filed as Exhibits.

Exhibit 1 - Joint Filing Agreement, dated as of January 17, 2025, signed by each of the Reporting Persons, incorporated by reference to Exhibit 1 to the Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Shalom Auerbach

Signature: **/s/ Shalom Auerbach**

Name/Title: **Shalom Auerbach**

Date: **08/18/2025**

Einodmil LLC

Signature: **/s/ Shalom Auerbach**

Name/Title: **Shalom Auerbach/Principal**

Date: **08/18/2025**